Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
The company had incurred a loss of $1.32 per share in the year-ago quarter. Axsome's total revenues surged 81% year over year to $104.8 million in the third quarter, beating the Zacks Consensus Estimate of $99 million. The increase in revenues can be attributed to strong sales of Auvelity (AXS-05). Shares of Axsome were up 9.4% on Nov. 12 owing to the better-than-expected results and strong sales uptake of Auvelity. AXSM stock has rallied 25% so far this year against the industry's decline of 0.9%. Image Source: Zacks Investment Research Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Total revenues in the third quarter consisted of product revenues from Auvelity and Sunosi (solriamfetol) and royalty revenues. Net product revenues were $103.7 million in the quarter compared with $57.1 million reported in the year-ago period. The figure beat our model estimate of $94 million. This marks the first time that Axsome generated product revenues of m
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $112.00 to $116.00. They now have an "outperform" rating on the stock.MarketBeat
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
AXSM
Earnings
- 11/12/24 - Beat
AXSM
Sec Filings
- 11/20/24 - Form 4
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- AXSM's page on the SEC website